InsiderTrades.com logo
Paul F. Lizzul net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Paul Lizzul Biography and Net Worth

Chief Medical Officer of AnaptysBio

Paul leads the company’s development organization, including clinical medicine, clinical operations, regulatory affairs, pharmacology and toxicology functions. Prior to Anaptys, he has served as global development lead for Inflammation at Amgen, chief medical officer of Sienna Biopharmaceuticals and senior medical director at Kythera Biopharmaceuticals. Paul served as assistant professor of Dermatology and conducted clinical research at Tufts Medical Center. He is a board-certified dermatologist, a faculty member of the American Academy of Dermatology and has served on the United States Food and Drug Administration (FDA) Dermatology and Ophthalmic Drugs Advisory Committee. Paul received his M.D., Ph.D. in molecular genetics and MPH in epidemiology from the Robert Wood Johnson Medical School at Rutgers. He has also earned an MBA in entrepreneurship from the Rutgers Business School.

What is Paul F. Lizzul's net worth?

The estimated net worth of Paul F. Lizzul is at least $314,735.12 as of September 23rd, 2024. Dr. Lizzul owns 15,398 shares of AnaptysBio stock worth more than $314,735 as of May 24th. This net worth approximation does not reflect any other investments that Dr. Lizzul may own. Additionally, Dr. Lizzul receives an annual salary of $656,360.00 as Chief Medical Officer at AnaptysBio. Learn More about Paul F. Lizzul's net worth.

How old is Paul F. Lizzul?

Dr. Lizzul is currently 49 years old. There are 5 older executives and no younger executives at AnaptysBio. The oldest executive at AnaptysBio is Mr. Dennis M. Mulroy, Chief Financial Officer, who is 69 years old. Learn More on Paul F. Lizzul's age.

What is Paul F. Lizzul's salary?

As the Chief Medical Officer of AnaptysBio, Inc., Dr. Lizzul earns $656,360.00 per year. There are 2 executives that earn more than Dr. Lizzul. The highest earning executive at AnaptysBio is Mr. Daniel R. Faga, President, CEO & Director, who commands a salary of $867,120.00 per year. Learn More on Paul F. Lizzul's salary.

How do I contact Paul F. Lizzul?

The corporate mailing address for Dr. Lizzul and other AnaptysBio executives is 10421 PACIFIC CENTER COURT SUITE 200, SAN DIEGO CA, 92121. AnaptysBio can also be reached via phone at (858) 362-6295 and via email at investors@anaptysbio.com. Learn More on Paul F. Lizzul's contact information.

Has Paul F. Lizzul been buying or selling shares of AnaptysBio?

Paul F. Lizzul has not been actively trading shares of AnaptysBio during the last ninety days. Most recently, Paul F. Lizzul sold 1,500 shares of the business's stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $38.67, for a transaction totalling $58,005.00. Following the completion of the sale, the insider now directly owns 15,398 shares of the company's stock, valued at $595,440.66. Learn More on Paul F. Lizzul's trading history.

Who are AnaptysBio's active insiders?

AnaptysBio's insider roster includes Daniel Faga (President & CEO), Dennis Fenton (Director), Paul Lizzul (Chief Medical Officer), Eric Loumeau (COO), Dennis Mulroy (CFO), Hollings Renton (Director), and Hamza Suria (CEO). Learn More on AnaptysBio's active insiders.

Are insiders buying or selling shares of AnaptysBio?

In the last twelve months, AnaptysBio insiders bought shares 3 times. They purchased a total of 345,802 shares worth more than $10,928,220.98. In the last twelve months, insiders at the biotechnology company sold shares 7 times. They sold a total of 37,840 shares worth more than $1,342,179.10. The most recent insider tranaction occured on January, 2nd when Director Ecor1 Capital, Llc bought 6,646 shares worth more than $86,065.70. Insiders at AnaptysBio own 33.5% of the company. Learn More about insider trades at AnaptysBio.

Information on this page was last updated on 1/2/2025.

Paul F. Lizzul Insider Trading History at AnaptysBio

See Full Table

Paul F. Lizzul Buying and Selling Activity at AnaptysBio

This chart shows Paul F Lizzul's buying and selling at AnaptysBio by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1Q2-$100k-$50k$0$50k$100kTotal Insider BuyingTotal Insider Selling

AnaptysBio Company Overview

AnaptysBio logo
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
Read More

Today's Range

Now: $20.44
Low: $20.03
High: $20.75

50 Day Range

MA: $19.36
Low: $16.24
High: $22.22

2 Week Range

Now: $20.44
Low: $12.21
High: $41.31

Volume

357,651 shs

Average Volume

600,947 shs

Market Capitalization

$600.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A